Could a Cancer-Killing pill stop colon cancer before it starts?

NCT ID NCT05630794

Recruiting now Prevention Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests the safety of a drug called ONC201 (dordaviprone) in 36 adults at high risk for colorectal cancer due to familial adenomatous polyposis (FAP) or a history of many polyps. The drug aims to kill precancerous cells without harming normal ones. Researchers will also check if polyps shrink or change after 12 weeks of treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL ADENOMATOUS POLYP are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenomatous colon polyp Adenomatous Polyposis Coli classic familial adenomatous polyposis colorectal adenoma colorectal carcinoma colorectal neoplasm polyposis colorectal cancer prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL ADENOMATOUS POLYP COLORECTAL CARCINOMA FAMILIAL ADENOMATOUS POLYPOSIS MULTIPLE ADENOMATOUS POLYPS

Contacts and locations

Locations

Cleveland Clinic Foundation
RECRUITING

Cleveland, Ohio, 44195, United States
Ohio State University Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43210, United States
Rhode Island Hospital
NOT_YET_RECRUITING

Providence, Rhode Island, 02903, United States
University of Michigan Rogel Cancer Center
RECRUITING

Ann Arbor, Michigan, 48109, United States
Washington University School of Medicine
NOT_YET_RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.